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Introduction
Breast cancer was the most frequently diagnosed cancer 
in women in 2015 [1–3]. An estimated 231,840 women 
were expected to be diagnosed with the breast cancer in 
the United States [1, 4]. Although the survival rate is 
improving, breast cancer is still the second major cause 
of cancer- related death in women [3, 5], largely due to 
the invasive nature and the high rate of metastasis in 
breast cancers [6]. If cancer spreads to the lymph nodes 
around the clavicle or to the other organs (distant stage), 
the overall median survival is low, ranging from 
15–27 months [7–9]. On the other hand, if the cancer 
has not spread to lymph nodes (early stage), the overall 
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Abstract
The goal of this study is to establish a method for predicting overall survival 
(OS) and disease- free survival (DFS) in breast cancer patients after surgical 
operation. The gene expression profiles of cancer tissues from the patients, who 
underwent complete surgical resection of breast cancer and were subsequently 
monitored for postoperative survival, were analyzed using cDNA microarrays. 
We detected seven and three probes/genes associated with the postoperative OS 
and DFS, respectively, from our discovery cohort data. By incorporating these 
genes associated with the postoperative survival into MammaPrint genes, often 
used to predict prognosis of patients with early- stage breast cancer, we con-
structed postoperative OS and DFS prediction models from the discovery cohort 
data using a Cox proportional hazard model. The predictive ability of the models 
was evaluated in another independent cohort using Kaplan–Meier (KM) curves 
and the area under the receiver operating characteristic curve (AUC). The KM 
curves showed a statistically significant difference between the predicted high- 
and low- risk groups in both OS (log- rank trend test P = 0.0033) and DFS 
(log- rank trend test P = 0.00030). The models also achieved high AUC scores 
of 0.71 in OS and of 0.60 in DFS. Furthermore, our models had improved KM 
curves when compared to the models using MammaPrint genes (OS: P = 0.0058, 
DFS: P = 0.00054). Similar results were observed when our model was tested 
in publicly available datasets. These observations indicate that there is still room 
for improvement in the current methods of predicting postoperative OS and 
DFS in breast cancer.
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survival increases substantially [1]. Therefore, early detec-
tion of the cancer plays an important role in extending 
a patient’s life expectancy.
Currently, surgery is the primary treatment for breast 
cancer without metastasis [4]. Either breast- conserving 
surgery (surgical removal of the tumor and surrounding 
tissue) or mastectomy (surgical removal of the breast) is 
performed [10]. However, even in cases of complete sur-
gical resection, postoperative overall survival (OS) and 
disease- free survival (DFS) can vary greatly among patients 
[11, 12]. Previous studies have shown that breast cancer 
can be classified into subclasses based on their gene expres-
sion profiles [13–16], and highly significant differences 
in OS and DFS can be observed between these subclasses 
[14]. Sorlie et al. reported that a basal group of breast 
cancer patients categorized by expression of genes associ-
ated with myoepithelial cells, KRT5 (keratin 5), KRT17 
(keratin 17), CNN1 (calponin 1), CAV1 (caveolin), and 
LAMB1 (laminin), is most aggressive with a poor DFS 
and OS [14]. In addition, several genetic tests using gene 
expression profiles have been developed to predict clinical 
outcomes [17, 18]. As one of the tests, MammaPrint [19] 
was developed as a diagnostic tool to predict prognosis 
of breast cancer for OS and DFS using the expression 
data for 70 genes [20]. However, to our knowledge, the 
analyses of the subsequent improved prediction models 
have yet to be reported.
Here, we identified genes associated with the postopera-
tive OS and DFS from our gene expression data of breast 
cancer patients, who underwent complete surgical resection 
and whose subsequent postoperative survival was recorded. 
By incorporating the genes associated with the postopera-
tive OS and DFS, as well as five genes associated with a 
poor DFS and OS reported by Sorlie et al. [14], into the 
MammaPrint gene set [21], we constructed prediction 
models from our discovery cohort using a Cox propor-
tional hazard model and investigated whether the models 
were improved. The predictive ability of our models was 
evaluated in several independent cohorts using both 
Kaplan–Meier (KM) curves and the area under the receiver 
operating characteristic curve (AUC). Not only were both 
of our models for OS and DFS validated in the independ-
ent test set, but our models also showed improved KM 




In the first discovery cohort, primary breast cancers were 
obtained with informed consent from 81 patients who 
were treated at the Department of Breast Surgery, Cancer 
Institute Hospital of Japanese Foundation for Cancer 
Research, Tokyo (Table S1). Clinical information was 
obtained from medical records as previously reported 
[22]. In the second discovery cohort, breast cancer tissue 
samples from core needle biopsy or surgical biopsy and 
corresponding clinical information was obtained from 
three hospitals (The Cancer Institute Hospital of JFCR, 
Sapporo Breast Surgery Clinic, and Sapporo Medical 
University) after each patient had provided informed 
consent [23]. A total of 16 cancer samples that had 
been confirmed histologically as invasive breast cancer 
were used in the second discovery cohort (Table S1). 
A piece of cancer tissue was taken from each patient 
at the time of biopsy, before chemotherapy, as described 
previously [23]. The samples used in the first and second 
discovery cohorts were immediately embedded in 
TissueTek OCT compound (Sakura, Tokyo, Japan), fro-
zen, and stored at −80°C. The frozen tissues were sliced 
into 8 μm sections using a cryostat (Sakura) and then 
stained with H&E for histological examination. Breast 
cancer cells were selectively enriched for our experiments 
using the EZ cut system with a pulsed UV narrow beam 
focus laser (SL Microtest GmbH, Germany) according 
to the manufacturer’s protocols. A mixture of RNA iso-
lated from normal breast ductal cells of breast cancer 
patients served as a normal control as described previ-
ously [22, 23].
Validation cohorts were obtained from the GEO (acces-
sion GSE42568 [24] and GSE1456 [25]) and TCGA 
(https://cancergenome.nih.gov/) databases. The GSE42568 
cohort has 104 patients with breast cancer, of which 48 
patients experienced relapse and 35 patients died. The 
GSE1456 cohort has 159 patients with breast cancer, of 
which 40 patients experienced relapse and 29 patients 
died. These cohorts were used as validation sets for both 
the OS and DFS prediction models. One gene in the 
MammaPrint gene set, PALM2, was excluded from the 
GSE1456 validation analysis due to low signal intensities 
and missing values. The TCGA cohort has 1090 breast 
cancer patients with RNA- seq and clinical information, 
of which 151 patients died. As there was no information 
regarding relapse, this cohort was used as a validation 
set for only the OS prediction models. Six genes 
(QSCN6L1, KNTC2, ORC6L, GPR126, PECI, and ZNF533) 
in the MammaPrint gene set were excluded from the 
TCGA validation analysis due to low signal intensities 
and missing values.
Microarray gene expression data
Microarray experiments were performed as previously 
reported [22, 23]. We used mixture of RNAs isolated 
from normal breast ductal cells of breast cancer patients 
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as universal reference RNA (URR) for the microarray 
experiments. Briefly, cDNAs derived from breast cancer 
cells and URR were labeled with Cy5 and Cy3, respec-
tively. Equal amounts (2.5 μg for each microarray slide) 
of Cy5- and Cy3- labeled cDNA were combined, and then 
the mixed cDNA was hybridized for 14–16 h at 42°C on 
microarray composed of six glass slides with 27,648 cDNA 
probes. After hybridization, the microarrays were scanned 
and the fluorescence signals were digitalized using the 
Array Scanner Generation III (Amersham) and ArrayVision 
computer program (Amersham), as described previously 
[26].
To correct for bias between microarrays, quantile 
normalization [27] was applied to all microarray data 
for each Cy and slide set using R software. The signal 
ratio of each probe was calculated according to the 
following procedure. (1) If the both Cy5 and Cy3 signal 
of a probe were less than 10,000, the ratio was handled 
as missing value. (2) If only one of either Cy3 or Cy5 
signal was less than 10,000, the lower signal was con-
verted to 10,000. (3) The ratio was calculated by the 
Cy5/Cy3 signal intensity. Next, the log2- transformed ratio 
was converted to a z- score for each microarray slide, 
the z- score conversion was performed using following 
formula:
where z is the z- score for probe ji, ji is log2- transformed 
ratio of a probe, J̄ is mean ratio for log2- transformed 
ratio of all probes in the microarray slide, and σ is the 
standard deviation from the mean. In addition, these data 
were further normalized per gene in each dataset by the 
z transformation for cross- platform analysis.
Statistical analysis
Both OS and DFS were investigated using Cox propor-
tional hazard models with “time since diagnosis” as the 
underlying time scale. We first performed gene selection 
through the following steps: (1) The most significantly 
differentially expressed genes under different conditions 
(OS: survival and dead, DFS: relapse and nonrelapse) using 
a Cox proportional hazard model from the first discovery 
cohort data (P < 0.0003). (2) Genes showing effects in 
the same direction as genes detected in step 1 from the 
second discovery cohort data. (3) Genes showing q < 0.2 
in the combined discovery cohort data. The time since 
diagnosis for OS was then calculated from the date of 
postoperative check up to the date of death or the follow-
 up cutoff, and that for DFS was calculated from the date 
of postoperative check up to the date of distant organ 
relapse.
Using genes determined under three selection conditions 
as described above, we calculated a prognostic index for 
each sample as defined by
where βi is the estimated regression coefficient of each 
gene using a Cox proportional hazard model in the com-
bined discovery cohort data, and Xi is the z- transformed 
score of the gene. The prognostic index was calculated 
in each sample of the combined discovery cohort. We 
classified samples into two groups (high- and low- risk 
groups) by an optimal cutoff value of the prognostic index 
[28]. The optimal cutoff value indicated a minimum log- 
rank trend test P- value by comparing differences between 
high- and low- risk groups in the combined discovery 
cohort in OS and DFS, respectively. These optimal cutoff 
values were used for the validation analysis of our OS 
and DFS prediction models.
KM curves were constructed to illustrate difference in 
survival in OS and DFS. The log- rank test was used to 
compare the different conditions. A P- value of 0.05 or 
less was considered statistically significant. Moreover, the 
receiver operator characteristic (ROC) curves [29] and 
the area under the curve (AUC) were indicated as the 
discriminative accuracy of these survival prediction models. 
All of these statistical analyses in this study were conducted 




The first discovery cohort was composed of 81 patients 
with breast cancer, who underwent complete surgical 
resection. The surviving patients’ progress was followed 
up to 11 years. The overall 11- year OS and DFS rates 
for all patients in discovery cohort were 86.4% (70 patients) 
and 76.5% (62 patients), respectively. While the second 
discovery cohort was composed of 16 breast cancer patients, 
the surviving patients’ progress was followed up to 3 years. 
The overall 3- year OS and DFS rates for all patients in 
the second discovery cohort were 50.0% (8 patients) and 
68.8% (11 patients), respectively (Table 1). Of the patients 
that died in the discovery cohorts, relapse was the cause 
of all 11 in the first cohort, but only 4 of the 8 in the 
second cohort (Table 1).
Genes affecting postoperative OS and DFS
To correct for bias between microarrays, we first applied 
quantile normalization to all microarray data for each Cy 
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and slide set. The signal ratio of each probe was then 
calculated according to the following procedure. If both 
the Cy5 and Cy3 signal of a probe were < 10,000, the 
ratio was handled as missing value. If only one of the 
Cy3 or Cy5 signal was < 10,000, the lower signal was 
converted to 10,000. The ratio was calculated by the Cy5/
Cy3 signal intensity. The log2- transformed ratio was con-
verted to a z- score for each microarray slide, and further 
converted to a z- score for each gene in each data for 
cross- platform study (see the Materials and Methods). 
More than half of probes in both groups (OS: dead and 
survival, DFS: relapse and nonrelapse) were missing values 
and were excluded from this study. Of the 27,647 probes, 
9980 and 9973 were used to in the final gene selection 
for postoperative OS and DFS prediction models in the 
first discovery cohort; 15,589 and 15,102 in the second 
discovery cohort, respectively (Table 1). We examined 
probes/genes associated with postoperative OS and DFS 
using a Cox proportional hazard model with time since 
diagnosis (see Materials and Methods). As a final result, 
we detected seven (LAMB1, TMEM189-UBE2V, ESYT1, 
TUBB2A, ADAM9, JUP, and SMARCA2) and three 
(KIAA0196, LAMB1, and MTMR3) genes associated with 
postoperative OS and DFS, respectively (Table 2). The 
laminin subunit beta 1, encoded by LAMB1, was detected 
as a gene associated with both postoperative OS and DFS 
(OS: q = 0.041, HR = 0.67, 95% CI = 0.52–0.87; DFS: 
q = 0.18, HR = 0.59, 95% CI = 0.44–0.79; Table 2). The 
microarrays used in the first and second discovery cohorts 
were not designed with probes for several of the 
MammaPrint genes, and many others were excluded from 
the analysis due to low signal intensities and missing 
values. Of the 70 MammaPrint genes, 37 were included 
in the prediction model construction (Table S2). We esti-
mated the regression coefficients for these 37 MammaPrint 
genes in discovery and validation cohorts using a Cox 
proportional hazard model, and examined these genes’ 
correlations between the different cohorts using Pearson’s 
correlation test. Pearson’s correlation coefficients of 0.50 
(P = 0.0016) and 0.49 (P = 0.0019) were obtained in 
the GSE42568 validation cohort for OS and DFS, respec-
tively. Similar results were obtained in the GSE1456 vali-
dation cohort; Pearson’s correlation coefficients of 0.66 
(P = 1.03 × 10−3) and 0.65 (P = 1.49 × 10−5) for OS 
and DFS, respectively. These results showed positive cor-
relation between discovery and validation cohorts in both 
OS and DFS (Table S3).
Evaluation of postoperative OS and DFS 
prediction models
Based on the MammaPrint gene set, we constructed pre-
diction models for OS and DFS in the combined discovery 
cohort data using a Cox proportional hazard model. We 
calculated a prognostic index assigned to each subject by 
applying the MammaPrint gene set to OS and in DFS 
for each of the prediction models. Based on the prognostic 
index, we divided samples of the discovery cohort into 
high- and low- risk groups. The optimal cutoff values were 
detected by using the minimum log- rank trend test P- 
value and comparing the differences within survival in 
OS and DFS as determined by KM curves (OS: optimal 
cutoff = 6.59, minimum P < 1.11 × 10−16, Fig. 1A; DFS: 
optimal cutoff = 8.91, minimum P < 7.62 × 10−14, Fig. 1B). 
We also performed AUC estimations based on the prog-
nostic index. The AUC achieved in OS was 0.84 (95% 
CI = 0.73–0.95, Fig. 1C) and the AUC for DFS was 0.74 
(95% CI = 0.63–0.86, Fig. 1D). The ROC curve achieved 
a maximum sensitivity of 0.74 and specificity of 0.83 in 
OS (Fig. 1C), and a maximum sensitivity of 0.50 and 
specificity of 0.90 in DFS (Fig. 1D).
In order to further improve the MammaPrint gene set 
prediction models, we incorporated the seven and three 
genes detected to be associated with OS and DFS in our 
analysis (Table 2), and the five genes associated with a 
poor DFS and OS as reported by Sorlie et al. [14] to 
the MammaPrint gene set (Table S2), and constructed 
prediction models in the combined discovery cohort using 
a Cox proportional hazard model. We calculated a prog-
nostic index assigned to each subject by applying 48 genes 
(Tables 2 and S2) to OS and 44 genes to DFS (Table 2 
and Table S2) for each of the prediction models, and 
divided the samples of the discovery cohort into high- 
and low- risk groups. The optimal cutoff values were 
detected using the minimum log- rank trend test P- value 
when comparing the differences within survival in OS 
and DFS as determined by KM curves (OS: optimal cut-
off = 7.14, minimum P < 1.11 × 10−16, Figure 2A, DFS: 
Table 1. OS and DFS rates for all patients in the first and second discovery cohorts.
# patients OS DFS
Dead Survive # Probes Relapse Nonrelapse # Probes
First cohort 11 70 9980 19 62 9973
Second cohort 8 8 15,589 5 11 15,102
Combined cohort 19 78 10,337 24 73 10,611
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optimal cutoff = 6.90, minimum P < 1.11 × 10−15, Fig. 2B). 
We also performed AUC estimations based on the prog-
nostic index. The AUC achieved in OS was 0.92 (95% 
CI = 0.86–0.99, Fig. 2C) and the AUC for DFS was 0.80 
(95% CI = 0.70–0.90, Fig. 2D). The ROC curve achieved 
a maximum sensitivity of 0.79 and specificity of 0.91 in 
OS (Fig. 2C), and a maximum sensitivity of 0.79 and 
specificity of 0.70 in DFS (Fig. 2D).
Validation of our prediction models using 
independent test sets
To ensure the generality of our prediction models, we 
applied our models to an additional three independent 
test datasets (validation cohorts). The independent valida-
tion sets were obtained from the GEO and TCGA data-
bases, and consisted of 104 patients (accession GSE42568 
[24]), 159 patients (accession GSE1456 [25]), and 1090 
patients (TCGA) with breast cancer. First, we examined 
whether prediction models using the MammaPrint gene 
set and the OS improved gene set were validated in the 
independent test sets for OS. We calculated a prognostic 
index for each subject by applying the MammaPrint gene 
set and the OS improved gene set to each of the predic-
tion models. Using the optimal cutoff values predetermined 
in the discovery cohort (MammaPrint gene set = 6.59, 
OS improved gene set = 7.14), the samples of the inde-
pendent test dataset were divided into high- and low- risk 
groups. The difference within survival in OS was deter-
mined by KM curves, showing statistically significant dif-
ference for both the prediction models using the 
MammaPrint gene set (log- rank trend P = 0.0058, 
HR = 0.27, 95% CI = 0.10–0.73, Fig. 3A) and using the 
OS improved gene set (log- rank trend P = 0.0033, 
HR = 0.25, 95% CI = 0.094–0.68, Fig. 3B) in the GSE42568 
cohort. Similar results were also obtained in the GSE1456 
cohort, showing a statistically significant difference for 
both the prediction models using the MammaPrint gene 
set (log- rank trend P = 0.0061, HR = 0.35, 95% CI = 0.16–
0.77, Fig. S1A) and using the OS improved gene set 
(log- rank trend P = 0.00058, HR = 0.29, 95% CI = 0.14–
0.62, Fig. S1B). In addition, similar results were obtained 
in TCGA cohort, showing a statistically significant differ-
ence for the prediction model using the OS improved 
gene set (log- rank trend P = 0.035, HR = 0.66, 95% 
CI = 0.45–0. 97, Fig. S2B), although the model using the 
MammaPrint gene set did not show a statistically signifi-
cant difference (log- rank trend P = 0.41, HR = 1.20, 95% 
CI = 0.78–1.83, Fig. S2A). The AUC achieved in the 
prediction model using the MammaPrint gene set was 
0.66 (95% CI = 0.55–0.77, Fig. 3C) in GSE42568, 0.76 
(95% CI = 0.67–0.85, Fig. S1C) in GSE1456, and 0.55 
(95% CI = 0.50–0.60, Fig. S2C) in TCGA. The AUC for 
the OS improved gene set was 0.71 (95% CI = 0.60–0.82, 
Fig. 3D) in GSE42568, 0.78 (95% CI = 0.69–0.87, Fig. 
S1D) in GSE1456, and 0.53 (95% CI = 0.47–0.58, Fig. 
S2D) in TCGA. In OS, an improvement in the risk pre-
diction ability was observed using the OS improved gene 
set model.
In a similar way, for DFS, we compared prediction 
model using the MammaPrint gene set to that using the 
DFS improved gene set in the validation cohorts. As 
described previously, based on the optimal cutoff values 
predetermined in the discovery cohort (MammaPrint gene 
Table 2. Genes affecting postoperative OS and DFS using Cox proportional hazard models.
Gene symbol (Gene 
ID)
(1) P- value in first 
discovery cohort





q- value HR 95% CI
OS
LAMB1 (3912) 1.27 × 10−06 −1.31 −0.075 0.041 0.67 0.52–0.87
TMEM189-UBE2V1 
(387522)
2.95 × 10−05 1.79 0.04 0.034 2.20 1.34–3.60
ESYT1 (23344) 0.00012 1.30 0.38 0.042 2.02 1.27–3.21
JUP (3728) 0.00018 1.01 0.71 0.0012 2.43 1.62–3.64
SMARCA2 (6595) 0.00020 −1.45 −0.15 0.00046 0.29 0.18–0.48
TUBB2A (7280) 0.00022 1.32 0.33 0.045 1.96 1.24–3.10
ADAM9 (8754) 0.00024 1.1280 0.04675 0.071 1.74 1.16–2.62
DFS
KIAA0196 (9897) 5.52 × 10−05 0.90 0.067 0.14 2.31 1.55–3.44
MTMR3 (8897) 6.33 × 10−05 −1.04 −0.32 0.17 0.43 0.28–0.67
LAMB1 (3912) 0.00025 −0.60 −0.42 0.18 0.59 0.44–0.79
We performed gene selection through the following steps: (1) The top significantly differentially expressed genes under different conditions (OS, 
survival and dead; DFS, relapse and nonrelapse) using a Cox proportional hazard model from the first discovery cohort data (P < 0.0003). (2) Genes 
showing the effects in the same direction as genes detected in step 1 from the second discovery cohort. (3) Genes showing q < 0.2 in the combined 
discovery cohort. HR, hazard ratio.
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set = 8.91, DFS improved gene set = 6.90), we divided 
the samples of the independent dataset into high- and 
low- risk groups. The difference within survival in DFS 
was determined by KM curves. As is the case with the 
OS, the KM curves showed a statistically significant 
difference for both the models using the MammaPrint 
gene set (log- rank trend P = 0.00078, HR = 0.16, 95% 
CI = 0.05–0.54, Fig. 4A) and the DFS improved gene 
set (log- rank trend P = 0.00020, HR = 0.22, 95% 
CI = 0.089–0.52, Fig. 4B) in the GSE42568 cohort. Similar 
Figure 1. The Kaplan–Meier curves and the receiver operator characteristic curves for the prediction models using the MammaPrint gene set. Based 
on the MammaPrint gene set, prediction models were constructed from our combined discovery cohort data using a Cox proportional hazard model. 
A prognostic index was assigned to each subject was calculated by applying the MammaPrint gene set to each of the prediction models. Based on 
this prognostic index, the optimal cutoff values indicated by a minimum log- rank trend test P- value were determined by comparing the difference 
between high- (red) and low- risk (black) groups in the combined discovery cohort for cumulative overall survival (OS) (A) and disease- free survival (DFS) 
(B). OS: optimal cutoff = 6.59, minimum P < 1.11 × 10−16, DFS: optimal cutoff = 8.16, minimum P = 7.99 × 10−15. The AUC achieved in OS was 0.84 
(95% CI = 0.73 to 0.95) (C) and the AUC for DFS was 0.68 (95% CI = 0.56–0.81) (D). The receiver operator characteristic curve achieved a maximum 
sensitivity of 0.74 and specificity of 0.83 in OS (C), and a maximum sensitivity of 0.54 and specificity of 0.81 in DFS (D).
(a) (b)
(c) (d)
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results were obtained in the GSE1456 cohort, showing 
a statistically significant difference for the prediction model 
using the DFS improved gene set (log- rank trend 
P = 0.0075, HR = 0.36, 95% CI = 0.17–0.79, Fig. S3B). 
The model using the MammaPrint gene set did not show 
a statistically significant difference (log- rank trend 
Figure 2. The Kaplan–Meier curves and the receiver operator characteristic curves for the prediction models using our improved gene sets. On the 
basis of our improved gene sets, prediction models were constructed from our combined discovery cohort data using a Cox proportional hazard 
model. Prognostic index assigned to each subject was calculated by applying the improvement related genes to each of the prediction models. Based 
on this prognostic index, optimal cutoff values indicated by a minimum log- rank trend test P- value were determined by comparing the difference 
between high- (red) and low- risk (black) groups in the combined discovery cohort for cumulative overall survival (OS) (A) and disease- free survival (DFS) 
(B). OS: optimal cutoff = 7.14, minimum P < 1.11 × 10−16, DFS: optimal cutoff = 9.60, minimum P = 7.99 × 10−15. The AUC achieved in OS was 0.92 
(95% CI = 0.86–0.99) (C) and the AUC for DFS was 0.72 (95% CI = 0.60–0.84) (D). The receiver operator characteristic curve achieved a maximum 
sensitivity of 0.79 and specificity of 0.91 in OS (C), and a maximum sensitivity of 0.79 and specificity of 0.62 in DFS (D).
(a) (b)
(c) (d)
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P = 0.27, HR = 0.52, 95% CI = 0.16–1.70, Fig. S3A). 
The AUCs achieved for the MammaPrint gene set models 
was then 0.63 (95% CI = 0.51–0.75, Fig. 4C) in GSE42568 
and 0.73 in GSE1456 (95% CI = 0.64–0.82, Fig. S3C). 
The AUC for that using the DFS improved gene set was 
0.59 in GSE42568 (95% CI = 0.47–0.71, Fig. 4D) and 
0.72 in GSE1456 (95% CI = 0.63–0.80, Fig. S3D). Similar 
outcome was observed in DFS for KM curves as in OS. 
These results suggest that there is still much room for 
improvement in the current methods for prediction of 
postoperative OS and DFS in breast cancer patients.
Some traditional clinical markers, such as ER/PR, HER2, 
node stage, and tumor size, have been approved to affect 
clinical outcome of breast cancer [31–35]. As we were 
able to obtain specific phenotypes (ER, HER2, and grade) 
of breast cancers from a validation cohort (GSE1456 [25]), 
we further investigated if our genes (OS: seven genes, 
DFS: three genes) could predict OS and DFS independently 
Figure 3. Verification our prediction models using the GSE42568 cohort (validation cohort) obtained from the GEO database in OS. Kaplan–Meier 
curves for the OS prediction models using the MammaPrint gene set (A) and using our OS improved gene set (B) when using GSE42568’s data for 
the risk prediction model verification. Receiver operator characteristic curves for the OS prediction models using the MammaPrint gene set (C) and 
using our OS improved gene set (D) when using GSE42568’s data for the risk prediction model verification.
(a) (b)
(c) (d)
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by comparing the specific phenotype with and without 
our findings, respectively (i.e., deviation from a multipli-
cative model). As a result, significant P- values were observed 
for our OS genes (Table S4), although there were no 
significant P- values in our DFS genes (note that even 
when the phenotypes were not considered, our DFS genes 
did not result in significant P- values). These results showed 
that our OS genes could predict OS independently. While 
it is still unclear whether or not our DFS genes alone 
could predict DFS independently, this DFS improved gene 
set was both validated using several independent cohorts, 
and superior the results using the MammaPrint gene set. 
These results showed that our DFS improved gene set 
contributed to an improvement to the prediction models 
using only the MammaPrint gene set.
We also examined the efficacy of the prediction models 
using the improved gene sets excluding the MamaPrint 
gene set. We calculated a prognostic index assigned to 
each subject by applying 11 genes to OS and 7 genes to 
DFS for each of the prediction models (Tables 2 and 
Figure 4. Verification our prediction models using the GSE42568 cohort (validation set) obtained from the GEO database in DFS. Kaplan–Meier curves 
for the DFS prediction models using the MammaPrint gene set (A) and using our DFS improved gene set (B) when using GSE42568’s data for the risk 
prediction model verification. Receiver operator characteristic curves for the DFS prediction models using the MammaPrint gene set (C) and using our 
DFS improved gene set (D) when using GSE42568’s data for the risk prediction model verification.
(a) (b)
(c) (d)
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S2), and divided the samples of the discovery cohort into 
high- and low- risk groups. The optimal cutoff values were 
detected using the minimum log- rank trend test P- value 
when comparing the differences within survival in OS 
and DFS as determined by KM curves (OS: optimal cut-
off = 3.46, minimum P = 1.11 × 10−15, DFS: optimal 
cutoff = 2.07, minimum P = 5.88 × 10−15). On the basis 
of these optimal cutoff values determined in the discovery 
cohort, we then divided the samples of the independent 
dataset into high- and low- risk groups. The differences 
within survival in OS and DFS were determined by KM 
curves. However, the KM curves did not show a statisti-
cally significant difference for both models (OS: log- rank 
trend P = 0.12, HR = 0.48, 95% CI = 0.19–1.23, Fig. 
S4A; DFS: log- rank trend P = 0.057, HR = 0.47, 95% 
CI = 0.21–1.04, Fig. S4B). The AUCs achieved in the OS 
and DFS models were 0.65 (95% CI = 0.53–0.77, Fig. 
S4C) and 0.51 (95% CI = 0.40–0.63, Fig. S4D), 
respectively.
Discussion
Despite complete surgical resection of the breast cancer, 
clinical outcome after surgical operation varies greatly 
among patients. This suggests that certain genes may play 
a key role in the prognosis of breast cancer, and the 
observed variation could be due to gene expression. 
Previous studies have reported several differentially 
expressed genes associated with OS and DFS using micro-
array expression data [14], and several genetic tests using 
gene expression profiles have been developed to predict 
clinical outcomes [17, 18]. One of the tests, MammaPrint 
[19], successfully classifies tumors into two groups (good 
prognosis and poor prognosis) for OS and DFS [20]. 
However, subsequent improvement of these prediction 
models has yet to be reported.
In order to identify additional genes that could improve 
current prediction models of OS and DFS, we investi-
gated the gene expression data of breast cancer patients 
using a Cox proportional hazard model. We detected 
seven and three genes associated with postoperative OS 
and DFS, respectively. One gene, LAMB1, was common 
to both OS and DFS gene sets, suggesting that this gene 
may be related to not only the sensitivity to the adjuvant 
therapy, but also to the malignant potential of the breast 
cancer cells. A previous study reported that overexpres-
sion of LAMB1 is associated with both poor OS and 
DFS in breast cancer [14]. In addition, Yunchao et al. 
reported that Ubiquitin1, encoded by UBQLN1, is associ-
ated with poor prognosis in breast cancer [36]. As this 
gene interacts with ubiquitin conjugating enzyme E2 
variant 1 (encoded by UBE2V1, which was detected as 
a gene associated with OS, Table 2), this UBE2V1 seems 
to be a novel molecular biomarker able to predict poor 
prognosis in breast cancer. While the other genes also 
have a possibility to be novel biomarkers, we did not 
find any additional supporting evidence in the current 
literature. Further functional analysis of the above genes 
might clarify the biological mechanism regarding the 
regulation of the prognosis of the patients with breast 
cancer.
We examined whether prediction models using the 
improved gene sets contributed to an improvement of the 
prediction models using only the MammaPrint gene set. 
To evaluate the effectiveness of our prediction models, we 
used KM curves and AUCs. Further verification using inde-
pendent datasets (validation cohorts) was necessary to validate 
the effectiveness of our prediction models and to show that 
our models were not overfit to our training data. We vali-
dated the effectiveness of our models using several inde-
pendent data obtained from the GEO and TCGA databases. 
This result suggests that there is still room for improvement 
for predicting postoperative OS and DFS in breast cancer, 
although it may be necessary to compare the models using 
our improved gene sets to those using the full set of 
MammaPrint genes for clinical use, as the expression of 
many were not available in our discovery cohort data and 
the validation cohort data obtained from the GEO and 
TCGA databases. In addition, cancer treatment and the 
response to treatment directly influence the subsequent 
outcome of the disease [37, 38]. Therefore, it could be 
suggested that our improved gene sets influence the outcome 
of specific breast cancer treatments rather than overall out-
come. Further investigation using response information to 
specific therapies should be required in the future.
Steroid hormone receptors (HRs; i.e., estrogen receptor 
or progesterone receptor) are important prognostic and 
predictive factors for response to endocrine therapy in the 
treatment of breast cancer [31]. The hormone receptor- 
positive tumors (HR- positive) generally have a favorable 
prognosis [32]. In addition, human epidermal growth factor 
receptor 2 (HER2) overexpression (HER2- positive) is also 
associated with worse clinical outcome (worse prognosis) 
of breast cancer [33, 34]. It has been statistically shown 
that the 10- year prognosis of patients is worse than that 
of those with HER2- negative [35]. Although we could not 
obtain the information in this study, we believe that pre-
diction models considering the HR and HER2 status could 
contribute to further improvements of our models. On 
the other hand, the development of next- generation 
sequencing technology [39–41] has facilitated the cost- 
effective comprehensive analysis of gene expression by 
RNA- seq. In the future, we believe that further replication 
of this analysis using larger sample sizes will lead to a 
greater improvement in the performance of our prediction 
models for its practical clinical use.
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